Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05015686
Other study ID # PRO-VZV-4002
Secondary ID
Status Enrolling by invitation
Phase Phase 3
First received
Last updated
Start date September 30, 2021
Est. completion date September 20, 2026

Study information

Verified date March 2024
Source Sinovac (Dalian) Vaccine Technology Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This a randomized, blind, controlled clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity of a two doses vaccination of investigational vaccine with 0,28 day, 0,42 day and 0,56 day immunization schedule in population aged ≥13 years old.


Description:

This study is a randomized, blind, controlled phase # clinical trial in population aged ≥13 years old. The experimental vaccine will be manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.A total of 2400 subjects aged 13 years and older will be enrolled with1200 subjects in 13 ~ 17 years old group and1200 subjects in 18 years and older group.960 subjects in each age group will be randomly divided into experimental group and control group according to 1:1 ratio,and subjects will receive two doses of vaccine with the immunization course of 0,28 days, 0,42 days or 0,56 days. An additional 240 subjects in each age group will be randomly divided into experimental group and control group according to 2:1 ratio to receive two doses of the experimental vaccine or placebo with the immunization course of 0, 70 days.In addition,400 subjects including 320 people of experimental group in different immunization course according to the difference of age and 80 people of placebo group according to the difference of age will be selected to collect blood about 3ml each time to evaluate immunity persistence of live attenuated varicella vaccines at 3 and 5 years after the whole immunization.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 2400
Est. completion date September 20, 2026
Est. primary completion date February 9, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 13 Years and older
Eligibility Inclusion Criteria: - Healthy population aged 13 years and above; - Proven legal identity; - The subjects and/or guardians can understand and voluntarily sign the informed consent form (For subjects aged 13-17 years, both subjects and guardians need to sign the informed consent form); Exclusion Criteria: - History of chickenpox or shingles; - Axillary temperature >37.0°C; - Already pregnant (including a positive urine pregnancy test) or are breastfeeding, planning to get pregnant within 6 months; - History of asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema; - Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc; - Autoimmune disease or immunodeficiency / immunosuppression; - Severe chronic diseases, severe cardiovascular diseases,hypertension(adult field measurement: SBP =140mmHg or diastolic blood pressure =90mmHg)and diabetes that cannot be controlled by drugs, liver or kidney diseases; - Family history of psychosis,severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; - Thyroid disease or history of thyroidectomy, asplenia, functional asplenia,asplenia or splenectomy resulting from any condition; - Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation; - Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months; - History of alcohol or drug abuse; - Receipt of blood products within in the past 3 months; - Participating in other drug/vaccine clinical trial; - Receipt of attenuated live vaccines in the past 28 days; - Receipt of inactivated or subunit vaccines in the past 7 days; - Onset of various acute or chronic diseases within 7 days prior to the study; - According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd
live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd
live varicella-zoster virus in trehalose,human serum albumin,sodium glutamate,sucrose,glucose,carbamide,arginine and injection water per injection
Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd
live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
Placebo
Sodium chloride and distilled water

Locations

Country Name City State
China Yucheng Center for Disease Control and Prevention Shangqiu Henan

Sponsors (1)

Lead Sponsor Collaborator
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Seroconversion rate of the antibody The seroconversion rate of the antibody 28 days among all subjects after the second vaccination. Day 28 after the whole schedule
Primary GMT of the antibody The GMT of the antibody 28 days among all subjects after the second vaccination. Day 28 after the whole schedule
Secondary GMI of the antibody GMI of the antibody 28 days among all subjects after the second vaccination. Day 28 after the whole schedule
Secondary Seroconversion rate, positive rate, GMT and GMI of the antibody Seroconversion rate, positive rate, GMT and GMI of the antibody among all subjects on day 28,day 42 and day 56 after the first vaccination. Day 28,Day 42 and day 56 after the first vaccination
Secondary Incidence of adverse reactions within 0~28 days after each dose Incidence of adverse reactions within 0~28 days after each dose vaccination with immunization course of 0,28 days ,0,42 days and 0,56 days. Within 0~28 days after each dose
Secondary Incidence of adverse reactions within 0~14 days after each dose vaccination Incidence of adverse reactions within 0~14 days after each dose vaccination with immunization course of 0,28 days ,0,42 days and 0,56 days Within 0~14 days after each dose
Secondary Incidence of grade 3 and above adverse reactions Incidence of grade 3 and above adverse reactions within 0~28 days after each dose vaccination with immunization course of 0,28 days ,0,42 days and 0,56 days. within 0~28 days after each dose
Secondary Incidence of serious adverse events Incidence of serious adverse events from vaccination to 6 months after the second vaccination with immunization course of 0,28 days ,0,42 days and 0,56 days From vaccination to 6 months after the second vaccination
See also
  Status Clinical Trial Phase
Completed NCT00792623 - Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM). Phase 2
Completed NCT00092430 - Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Phase 3
Completed NCT00384397 - A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Phase 3
Completed NCT00226499 - Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Phase 3
Completed NCT00402831 - ProQuad® Intramuscular vs Subcutaneous Phase 3
Not yet recruiting NCT06068608 - A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy Phase 1
Completed NCT00560755 - Safety Study of ProQuad® rHA in Infants (V221-037) Phase 3
Completed NCT00715234 - Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients N/A
Terminated NCT00258726 - Immune Responses to Two Dose Varivax +/- MMR-II Phase 1/Phase 2
Completed NCT03239873 - Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03) Phase 3
Completed NCT00751348 - Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Phase 3
Completed NCT00969436 - Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Phase 3
Completed NCT00566527 - Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Phase 3
Completed NCT01390857 - Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox) N/A
Completed NCT00127010 - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Phase 3
Completed NCT00578175 - Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Phase 2
Completed NCT00568334 - Study of Two Formulations of GSK Biologicals' Varicella Vaccine Phase 2
Completed NCT03114982 - The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age Phase 2
Completed NCT00483574 - Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers Phase 3
Completed NCT00126997 - Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Phase 4